Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND AVL-292 [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292

Study has passed its completion date and status has not been verified in more than two years.